For Cindy Whitehead, looking through rose-colored glasses is a way of life.
Known for her liberal use of the color pink across her businesses as well as her wardrobe, Whitehead is passionate about equalizing the playing field between genders when it comes to sexual health.
It was precisely this issue which got Whitehead, a lifelong pharma-tech entrepreneur, thinking about the disparities in the sexual health industry, and how she could effectively address them with a pink-hued pill she launched via her parent company, Sprout Pharmaceuticals.
Once she finally received FDA approval in August, 2015, Whitehead decided to sell her company to Valeant Pharmaceuticals for $1 billion, with the hope that her brand would be built into a women’s healthcare platform, which she says “didn’t end up happening.” According to various medical sources, Addyi has been disappointing in terms of sales, attributed in part to a lack of support from Valeant.
Listen to find out about her billion-dollar acquisition, her new venture the pink ceiling and her thoughts on entrepreneurship trends.